Hall Brett Matthew 4
Accession 0001790340-26-000030
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:32 AM ET
Size
5.4 KB
Accession
0001790340-26-000030
Research Summary
AI-generated summary of this filing
Immuneering (IMRX) CSO Brett Hall Receives 344,000-Share Award
What Happened Brett Matthew Hall, Chief Scientific Officer of Immuneering Corp (IMRX), was granted 344,000 derivative shares (reported as an "A"—award/grant) on February 3, 2026. The grant is reported at an acquisition price of $0.00 (no cash paid at grant). This is a compensation award rather than a market purchase or sale.
Key Details
- Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (filed within the typical two-business-day reporting window).
- Award size: 344,000 derivative shares; reported acquisition price: $0.00.
- Vesting: Vests in equal monthly installments over a four-year period commencing February 1, 2026; fully vested January 1, 2030 (per filing footnote).
- Shares owned after transaction: Not specified in the provided filing.
- Transaction code: A = Award/Grant; no exercise or sale occurred in this filing.
Context This filing documents a standard equity compensation grant to an executive. Such awards are common for aligning executive incentives with shareholder value; they do not represent an immediate purchase or sale of stock. Because these are derivative awards with a multi-year vesting schedule, they do not indicate an immediate change in share count available for sale.
Insider Transaction Report
- Award
Stock Option
[F1]2026-02-03+344,000→ 344,000 totalExercise: $4.91Exp: 2036-02-03→ Class A Common Stock (344,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.
Signature
Documents
Issuer
Immuneering Corp
CIK 0001790340
Related Parties
1- filerCIK 0001870437
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 8:32 AM ET
- Size
- 5.4 KB